Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — ZIOPHARM Oncology — Jefferies Immuno-Oncology Summit (April 2016)
18 slides from Alaunos Therapeutics's conference presentation, Apr 7, 2016
Slide 1: ZIOPHARM – Jefferies Immuno-Oncology Summit, April 2016
Exhibit 99.1 Exhibit Jefferies ZIOPHARM April 2016 99.1 Immuno-Oncology Summit
Slide 2: Forward-looking Statements
Forward-looking This Litigation “anticipates,” progress Company, antigen and approaches, competition including the 2any date when, events. presentation receptor hereof, ofbut Reform that ifthe Ad-RTS-IL-12, from atnot and could all, Company’s and Tstatements limited contains other “believes.” Act ce
Slide 3: ZIOPHARM Overview: Partnerships, Clinical Expertise and Technology
Partnerships Clinical Rapid CAR-T Biopharmaceutical Laurence Named Developed technology ZIOP/XON Previously pediatric Anderson expertise 3led program bone Clinical CEO Collaboration Collaborators marrow oncology in Cooper, Cancer professor Sleeping in-licensed immunotherapy, in to inJan Development
Slide 4: Technologies: Cytokines, Cellular Therapy and Combinations
Cytokines Technologies Cellular Safe Co-infuse Combinations Combine Target Neoantigens 4Overcome targets driver templates introduced cell TSwitches the Reduce cells mutations to therapy time execute with to burden immuno-receptor with generate multiple expressed tumor other on manufacturing cells th
Slide 5: Platforms: Patient-derived and Off-the-shelf Immunotherapies
Platforms Patient-derived Autologous B-cell Lentivirus Beauty Sleeping Antigens Understanding Off-the-shelf Myeloid Breast Glioblastoma not Donor 5N Recipients K be cellmalignancies known cancer TAdenovirus T malignancies known cell tocell products platforms I targets malignancies Neo-antigen platfo
Slide 6: Bio-engineering and Manufacturing Improvements
Bio-engineering Implementing improve –Leveraging Patient-derived Infusion Shorten Off-the-shelf In NK cells 6Match Shortened MDACC CMOs advance TInfusions cells one manufacturing performance Real donor cells manufacturing manufacturing (allogeneic) time manufacturing cells (autologous) and withbio-p
Slide 7: Pipeline: Addressing Unmet Medical Needs
Addressing Preclinical Ad-RTS-IL-12 Breast GBM Pediatric CAR CD19 Myeloid Merck Off-the-shelf NK Primary Combination Genetically-engineered TCR Target Sleeping Regulatory Other 7Modified Cells +3rd 1st 2nd 2017 Cancer Target Checkpoint NK malignancies Beauty Bacteria Generation Generation Generation
Slide 8: Ad-RTS-IL-12 Oral Activator Updated Data and Next Steps
Ad-RTS-IL-12 Oral Next Combination Pre-clinical anti-tumor Abstract *As Patients Early First Patient “On-target 8Updated of Activator patient Steps brain breast Dec accrual enrolled at response data toxicities” ASGCT tumor 15, data cancer achieved therapy for Ad-RTS-hiL-12 accelerating +2015 demonst
Slide 9: Sleeping Beauty Non-viral Gene Transfer Platform
Effector Golgi CAR Proteosome ER Antigen T Transposon Tumor Transposase receptors Steven Advantages Provides cell Lowers 9Has processing cells cell receptors theTCR TA. genetically the potential cell Co-signal Effector conduit into Rosenberg cost DNA of Transposon DNA lymphocytes Sleeping ofto funct
Slide 10: Sleeping Beauty: Long-term Follow-up Data for CD19 CAR-T
Long term Showed Non-viral Historical Recipient Autologous SB-modified Sleeping 10 favorable Beauty: Beauty 49% Donor Sleeping Controls follow-up HSCT CAR+T 3-year TAllogeneic First-in-human PFS Cell & Beauty data CD19-specific cells PFS and survival from reported T-cell OS HSCT trends 1st averaged
Slide 11: Intrexon/Merck KGaA Exclusive Collaboration
Intrexon/Merck Exclusive Merck KGaA $413 Tiered 11 million opt-in royalties KGaA, agreement per rights Darmstadt, up KGaA, product to during to lower-double develop Darmstadt, inGermany clinical milestones anddevelopment Germany digits to commercialize leadonIND net in CAR-T Economics sales filing C
Slide 12: Natural Killer Cells: Launching Off-the-shelf NK Trials
–Natural Launching OTS AML 12 Target Killing Cytokines, Build NK L on Killer killer Brain tumors, is cells promising Phase independent e.g., (NK) Brain Cells: & e.g., Ad-RTS-IL12 1IL-12 trials cells tumor Beyond with proof-of-principle are of ofloss tu aoff-the-shelf “fuel” specific CAR+ oror mismat
Slide 13: TCR: Perspective on Targeting Neoantigens
TCR: PERSPECTIVE Nat Science. Direct CAR+ 10% Indirect TCR+ 90% “Clinical “Success “Presently, 13 Med. ofTargeting T binding Tproteins binding cell 2015 cell evidence for 2016 use cell-based Apr of Jan private are nature the 3;348(6230):62-8 3;348(6230):69-74 supports 6;22(1):26-36 onSleeping within
Slide 14: Sleeping Beauty Approach for Neoantigen TCRs
Sleeping Patient Antigen T TCRs Nucleofection Non-viral Viral Target Beauty Low Rapid Customizable, Challenging 14cells cost delivery Ex Labor solid (recipient) presentation Beauty: approach vivo Sleeping tumor to intensive, SB11 gene able swap farthest Biopsy Limited High to transfer TCR in Co-cult
Slide 15: Examples of Neoantigen-specific TCRs to Target Solid Tumors
Examples of Melanoma: AHNAKS2580F(A*0201) Cholangiocarcinoma: ERBB2H473Y(A*0201) Molecular ERBB2IPE805G(DQB*0601) 15 Therapy AHNAKmut-TCR ERBB2mut-TCR neoantigen-specific 05ERBB2IPmut-TCR March 2016 TCRs to target solid tumors
Slide 16: Industrialization of Immunotherapies
Power-law The Traditional Sleeping Number 16 industrialization of Beauty curve trials Bio-pharma is critical of immunotherapies to patients Cost of distribution achieving n=1 response at scale of Number Next-generation immune Bio-pharma 1
Slide 17: Multiple Clinical Approaches and Current Trials
Multiple Current Administer T CAR NK TCR Cytokines Trial Three We 17T cells stand are have Ad-RTS-IL-12 initiated new launching combining Clinical immunotherapies an alone NK trials modified ecosystem expanding with cells inApproaches inmultiple our being different 2nd 2016: + immune veledimex abili
Slide 18: Jefferies ZIOPHARM April 2016 Immuno-Oncology Summit
Jefferies ZIOPHARM April 2016Immuno-Oncology Summit
ZIOPHARM Oncology — Jefferies Immuno-Oncology Summit (April 2016) on 6ix